Try our beta test site

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer (S1216)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Southwest Oncology Group
Sponsor:
Collaborators:
Millennium Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT01809691
First received: March 8, 2013
Last updated: January 31, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2027
  Estimated Primary Completion Date: March 2022 (Final data collection date for primary outcome measure)